Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hepa-B
- Development stage
- Phase 3
- Lead developer
- Incepta Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Hepa-B is a recombinant DNA vaccine developed to prevent Hepatitis B virus (HBV) infection. It is locally manufactured in Bangladesh by Incepta, following a technology transfer agreement with BioBridge company in Pune, India. The vaccine aims to provide a safe, cost-effective, and affordable alternative to imported Hepatitis B vaccines like Engerix-B, particularly in regions with high HBV prevalence such as Bangladesh. Clinical trials have demonstrated its non-inferiority in immunogenicity and safety compared to Engerix-B in healthy adults.
- Brand names
- Hepa-B
- Other names
- recombinant hepatitis b vaccineHBsAg vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Hepa-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepa-B.